EVH Stock Financial Analysis - Evolent Health, Inc. (NYSE) Stock

Evolent Health, Inc.
US ˙ NYSE ˙ US30050B1017

Overview
Evolent Health, Inc., based in the United States, operates within the healthcare sector, primarily focused on providing an integrated, value-based care platform to payers and providers. The company aids its partners in driving high-quality, lower-cost care by delivering comprehensive clinical and administrative solutions. Evolent Health’s key projects typically involve assisting organizations in transitioning from fee-for-service to value-based care models. This includes offering software, analytics, and clinical technology services that help manage risk and improve patient outcomes. Their strategic approach not only supports the operational needs of healthcare entities but also aligns with evolving regulatory and reimbursement frameworks, thereby facilitating a more sustainable and efficient healthcare system.
Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income
  • The revenue for Evolent Health, Inc. as of June 30, 2025 is 2,195.92 MM.
  • The operating income for Evolent Health, Inc. as of June 30, 2025 is -8.35 MM.
  • The net income for Evolent Health, Inc. as of June 30, 2025 is -130.45 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2025-06-30 2,195.92 -8.35 -130.45
2025-03-31 2,398.74 -1.79 -108.96
2024-12-31 2,554.74 2.33 -61.62
2024-09-30 2,464.25 26.39 -72.23
2024-06-30 2,353.87 41.12 -74.42
2024-03-31 2,175.86 26.09 -110.34
2023-12-31 1,963.90 30.78 -113.04
2023-09-30 1,790.27 1.37 -90.98
2023-06-30 1,631.84 6.56 -63.53
2023-03-31 1,482.65 11.75 -33.80
2022-12-31 1,352.01 -19.88 -19.16
2022-09-30 1,217.94 11.42 -13.46
2022-06-30 1,087.83 1.97 -28.62
2022-03-31 989.94 -4.47 -33.14
2021-12-31 907.96 -17.41 -37.60
2021-09-30 906.13 -20.31 -46.58
2021-06-30 923.24 -21.24 -70.89
2021-03-31 918.48 -17.82 -265.30
2020-12-31 924.64 -30.81 -334.25
2020-09-30 914.63 -48.08 -517.72
2020-06-30
Income Statement: EPS
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31 -0.81
2024-09-30 -0.91 -0.91
2024-06-30 -0.93 -0.93
2024-03-31 -1.25 -1.25
2023-12-31 -1.28
2023-09-30 -1.04 -1.04
2023-06-30 -0.74 -0.74
2023-03-31 -0.41 -0.41
2022-12-31 -0.20
2022-09-30 -0.15 -0.15
2022-06-30 -0.32 -0.32
2022-03-31 -0.38 -0.38
2021-12-31 -0.44
2021-09-30 -0.54 -0.53
2021-06-30 -0.83 -0.83
2021-03-31 -3.12 -3.12
2020-12-31 -3.94
2020-09-30 -6.24 -6.24
2020-06-30 -5.99 -5.99
Cash Flow: Operations, Investing, Financing
  • The cash from operating activities for Evolent Health, Inc. as of June 30, 2025 is -33.33 MM.
  • The cash from investing activities for Evolent Health, Inc. as of June 30, 2025 is -113.28 MM.
  • The cash from financing activities for Evolent Health, Inc. as of June 30, 2025 is 186.86 MM.
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2025-06-30 -33.33 -113.28 186.86
2025-03-31 18.42 -66.29 92.41
2024-12-31 18.77 -62.93 -0.56
2024-09-30 134.38 -49.05 -181.86
2024-06-30 176.23 -35.47 -210.22
2024-03-31 155.47 -30.28 -83.51
2023-12-31 142.58 -415.54 281.34
2023-09-30 88.90 -413.95 354.84
2023-06-30 24.91 -662.79 565.29
2023-03-31 37.91 -670.87 562.65
2022-12-31 -11.55 -259.12 131.54
2022-09-30 19.41 -309.03 203.29
2022-06-30 67.38 -55.84 30.85
2022-03-31 29.47 -44.97 -25.34
2021-12-31 38.75 -15.79 -29.55
2021-09-30 -40.76 36.36 -114.36
2021-06-30 -105.76 319.83 -128.86
2021-03-31 -43.85 317.83 -100.02
2020-12-31 -16.23 261.07 -11.86
2020-09-30 9.81 184.12 0.81
2020-06-30
Valuation Metrics : PE, PriceToBook, PriceToTBV
  • The p/book for Evolent Health, Inc. as of June 30, 2025 is 1.15.
  • The p/tbv for Evolent Health, Inc. as of June 30, 2025 is -1.50.
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2025-06-30 1.15 -1.50
2025-03-31 -17.92 0.93 -1.76
2024-12-31 1.03 -2.08
2024-09-30 -45.18 2.72 -5.70
2024-06-30 -20.85 1.87 -3.72
2024-03-31 -32.98 2.99 -5.99
2023-12-31 -41.74 3.46 -4.75
2023-09-30 -48.00 2.79 -3.69
2023-06-30 -99.83 3.01 -4.10
2023-03-31 -185.61 4.14
2022-12-31 -207.79 3.27 -8.80
2022-09-30 5.70 -44.78
2022-06-30 4.61 -32.28
2022-03-31 -76.68 4.16 -231.62
2021-12-31 -52.18 4.00 181.32
2021-09-30 -37.47 4.32 202.19
2021-06-30
2021-03-31 -9.00 3.87 269.70
2020-12-31 -7.07 3.81 -30.11
2020-09-30 -4.56 3.60 -45.50
2020-06-30 -4.73 3.70 -35.29
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
  • The ebit/ev for Evolent Health, Inc. as of June 30, 2025 is -0.05.
  • The ebit (3y)/ev for Evolent Health, Inc. as of June 30, 2025 is -0.06.
Period End (TTM) EBIT/EV EBIT (3y)/EV
2025-06-30 -0.05 -0.06
2025-03-31 -0.03 -0.06
2024-12-31 -0.04 -0.06
2024-09-30 -0.02 -0.03
2024-06-30 -0.04 -0.03
2024-03-31 -0.05 -0.02
2023-12-31 -0.04 -0.02
2023-09-30 -0.05 -0.02
2023-06-30 -0.04 -0.02
2023-03-31 -0.02 -0.03
2022-12-31 -0.02 -0.07
2022-09-30 -0.01 -0.06
2022-06-30 -0.01 -0.07
2022-03-31 -0.01 -0.08
2021-12-31 -0.02 -0.10
2021-09-30 -0.03 -0.09
2021-06-30
2021-03-31 -0.11 -0.10
2020-12-31 -0.14 -0.10
2020-09-30 -0.24 -0.10
2020-06-30 -0.20 -0.09
Management Effectiveness
  • The roa for Evolent Health, Inc. as of June 30, 2025 is -0.04.
  • The roe for Evolent Health, Inc. as of June 30, 2025 is -0.09.
  • The roic for Evolent Health, Inc. as of June 30, 2025 is -0.05.
  • The croic for Evolent Health, Inc. as of June 30, 2025 is 0.02.
  • The ocroic for Evolent Health, Inc. as of June 30, 2025 is 0.01.
Period End (TTM) ROA ROE ROIC CROIC OCROIC
2025-06-30 -0.04 -0.09 -0.05 0.02 0.01
2025-03-31 -0.02 -0.05 -0.03 -0.02 0.01
2024-12-31 -0.03 -0.06 -0.04 -0.05 0.07
2024-09-30 -0.03 -0.07 -0.04 -0.04 0.09
2024-06-30 -0.04 -0.10 -0.06 0.02 0.08
2024-03-31 -0.06 -0.13 -0.06 0.00 0.08
2023-12-31 -0.05 -0.11 -0.05 0.02 0.05
2023-09-30 -0.05 -0.10 -0.04 -0.04 0.01
2023-06-30 -0.03 -0.06 -0.04 -0.04 0.01
2023-03-31 -0.01 -0.03 -0.02 -0.04 0.02
2022-12-31 -0.01 -0.02 -0.01 -0.07 0.01
2022-09-30 -0.02 -0.05 -0.01 -0.07 0.02
2022-06-30 -0.03 -0.05 -0.03 0.04 0.07
2022-03-31 -0.03 -0.06 -0.04 -0.05 0.03
2021-12-31 -0.03 -0.08 -0.04 -0.01 -0.04
2021-09-30 -0.03 -0.11 -0.05 -0.13 -0.12
2021-06-30 -0.06 -0.11 -0.08 0.10 -0.12
2021-03-31 -0.29 0.19 -0.05
2020-12-31 -0.22 -0.36 -0.34 0.24 -0.02
2020-09-30 -0.30 -0.46 -0.51 0.19 0.01
2020-06-30 -0.31 -0.44 -0.50 0.02 0.01
Gross Margins
  • The gross margin for Evolent Health, Inc. as of June 30, 2025 is 0.15.
  • The net margin for Evolent Health, Inc. as of June 30, 2025 is -0.05.
  • The operating margin for Evolent Health, Inc. as of June 30, 2025 is -0.00.
Gross Margin
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Net Margin
The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
Operating Margin
The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) Gross Margin Net Margin Operating Margin
2025-06-30 0.15 -0.05 -0.00
2025-03-31 0.14 -0.02 0.00
2024-12-31 0.16 -0.03 0.00
2024-09-30 0.19 -0.03 0.01
2024-06-30 0.21 -0.05 0.01
2024-03-31 0.23 -0.06 0.02
2023-12-31 0.25 -0.05 0.01
2023-09-30 0.25 -0.04 0.01
2023-06-30 0.24 -0.04 0.01
2023-03-31 0.24 -0.02 0.01
2022-12-31 0.26 -0.01 0.01
2022-09-30 0.27 -0.01 0.01
2022-06-30 0.27 -0.03 0.00
2022-03-31 0.28 -0.03 -0.00
2021-12-31 0.24 -0.04 -0.02
2021-09-30 0.23 -0.05 -0.03
2021-06-30 0.23 -0.07 -0.04
2021-03-31 -0.29 -0.02
2020-12-31 0.23 -0.36 -0.03
2020-09-30 0.23 -0.55 -0.05
2020-06-30 0.23 -0.55 -0.08
Identifiers and Descriptors
Central Index Key (CIK)1628908
Other Listings
DE:9EH €8.10
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista